EM1034 / EpimAb Biotherap - LARVOL DELTA

A novel LY6G6D x CD3 bispecific T-cell engager demonstrates better tumor killing and minimal cytokine release than a benchmark molecule (AACR 2025) - "In vivo efficacy studies further demonstrated that EM1034 is more potent than the benchmark molecule in xenografted models with different LY6G6D expression levels. Taken together, this study support EM1034 as a promising molecule for the treatment of mCRC patients with LY6G6D positive MSS/MSI-L tumors."

IO biomarker • Colorectal Cancer • Oncology • Solid Tumor • LY6G6D • MSI

EpimAb Biotherapeutics Announces Four Upcoming Presentations at the 2025 American Association for Cancer Research Annual Meeting (GlobeNewswire) - "The posters will feature: 1) Clinical results for EMB-01, an EGFR x cMet bispecific antibody, in colorectal cancer; 2) Preclinical data for EM1031, a novel KLK2 x CD3 bispecific T-cell engager; 3) Preclinical data for a novel LY6G6D x CD3 bispecific T-cell engager and 4) Preclinical data for a novel TCR based bispecific platform."

P1/2 data • Preclinical • Colorectal Cancer